Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.
Curr Breast Cancer Rep., Dec;3(4):205-211 (2011)
Quantitative assessment of dynamic PET imaging data in cancer imaging.
Magn Reson Imaging., Nov;30(9):1203-15 (2012)
Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.
Magn Reson Imaging., Nov;30(9):1291-300 (2012)
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
J Natl Compr Canc Netw., Jul;10(7):821-9 (2012)
ACR Appropriateness CriteriaÂ® stage I breast carcinoma.
J Am Coll Radiol., Jul;9(7):463-7 (2012)
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.
EJNMMI Res., 2(1):34 (2012)
Accuracy of CT-based attenuation correction in PET/CT bone imaging.
Phys Med Biol., May;57(9):2477-90 (2012)
Advances in molecular imaging for breast cancer detection and characterization.
Breast Cancer Res., 14(2):206 (2012)
[Â¹â¸F]fluorodeoxyglucose positron emission tomography-computed tomography in breast cancer: when... and when not?
J. Clin. Oncol., Apr;30(12):1252-4 (2012)
Design considerations for using PET as a response measure in single site and multicenter clinical trials.
Acad Radiol., Feb;19(2):184-90 (2012)
Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
Nucl. Med. Biol., Oct;38(7):969-78 (2011)
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
J. Nucl. Med., Oct;52(10):1541-9 (2011)
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Clin. Cancer Res., Jul;17(14):4799-805 (2011)
ABNM celebrates 40th anniversary.
J. Nucl. Med., Jul;52(7):17N-8N (2011)
ABNM position statement: Nuclear medicine professional competency and scope of practice.
J. Nucl. Med., Jun;52(6):994-7 (2011)
Multiagent PET for risk characterization in sarcoma.
J. Nucl. Med., Apr;52(4):541-6 (2011)
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Clin. Cancer Res., Apr;17(8):2400-9 (2011)
Invasive breast cancer.
J Natl Compr Canc Netw., Feb;9(2):136-222 (2011)
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Clin Nucl Med., Mar;36(3):192-8 (2011)
Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
J Magn Reson Imaging., Nov;32(5):1124-31 (2010)
Breast cancer and hormonal stimulation: is glycolysis the first sign of response?
J. Nucl. Med., Nov;51(11):1663-4 (2010)
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Clin. Cancer Res., Nov;16(21):5260-8 (2010)
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
Clin. Cancer Res., May;16(10):2803-10 (2010)
Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.
J. Nucl. Med., Apr;51(4):521-7 (2010)
Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.
PET Clin., Jul;4(3):299-312 (2009)
Imaging tumor phenotype: 1 plus 1 is more than 2.
J. Nucl. Med., Oct;50(10):1567-9 (2009)
Blood flow-metabolism mismatch: good for the tumor, bad for the patient.
Clin. Cancer Res., Sep;15(17):5294-6 (2009)
Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.
J. Nucl. Med., Sep;50(9):1448-54 (2009)
Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
J. Nucl. Med., Aug;50(8):1267-75 (2009)
Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.
J. Nucl. Med., May;50(5):798-806 (2009)
The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions.
J. Nucl. Med., May;50(5):738-48 (2009)
The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1--overview, detection, and staging.
J. Nucl. Med., Apr;50(4):569-81 (2009)
Molecular imaging as a tool for translating breast cancer science.
Breast Cancer Res., 10 Suppl 1:S3 (2008)
Proliferation imaging to measure early cancer response to targeted therapy.
Clin. Cancer Res., Nov;14(22):7159-60 (2008)
Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.
Acad Radiol., Oct;15(10):1246-54 (2008)
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
J. Clin. Oncol., Sep;26(27):4449-57 (2008)
Tumor receptor imaging.
J. Nucl. Med., Jun;49 Suppl 2:149S-63S (2008)
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
J. Nucl. Med., Mar;49(3):367-74 (2008)
Locally advanced and inflammatory breast cancer.
J. Clin. Oncol., Feb;26(5):786-90 (2008)
FDG PET, PET/CT, and breast cancer imaging.
Radiographics., Oct;27 Suppl 1:S215-29 (2007)
Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.
Neuro-oncology., Feb;10(1):88-92 (2008)
Challenges in clinical studies with multiple imaging probes.
Nucl. Med. Biol., Oct;34(7):879-85 (2007)
Semin Nucl Med., Nov;37(6):470-6 (2007)
Positron emission tomography imaging as a cancer biomarker.
Expert Rev. Mol. Diagn., Sep;7(5):659-72 (2007)
Radiotracer breast cancer imaging: Beyond FDG and MIBI.
Phys Med., 21 Suppl 1:12-6 (2006)
Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.
Clin. Cancer Res., Jun;13(12):3460-9 (2007)
Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer.
Ann. Surg. Oncol., Oct;14(10):2985-93 (2007)
Beyond detection: novel applications for PET imaging to guide cancer therapy.
J. Nucl. Med., Jun;48(6):855-6 (2007)
A definition of molecular imaging.
J. Nucl. Med., Jun;48(6):18N, 21N (2007)
Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances.
AJR Am J Roentgenol., Jun;188(6):W503-5 (2007)
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
J Natl Compr Canc Netw., May;5 Suppl 1:S1-22; quiz S23-2 (2007)
Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
J. Nucl. Med., Jun;48(6):920-5 (2007)
Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.
Acad Radiol., Apr;14(4):398-405 (2007)
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Breast Cancer Res. Treat., Sep;105(1):87-94 (2007)
Current and future use of positron emission tomography (PET) in breast cancer.
J Mammary Gland Biol Neoplasia., Apr;11(2):125-36 (2006)
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Clin. Cancer Res., Oct;12(19):5608-10 (2006)
Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
J. Nucl. Med., Oct;47(10):1612-21 (2006)
Hypoxia imaging-directed radiation treatment planning.
Eur. J. Nucl. Med. Mol. Imaging., Jul;33 Suppl 1:44-53 (2006)
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
J. Nucl. Med., Jun;47(6):1059-66 (2006)
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
J. Clin. Oncol., Jun;24(18):2793-9 (2006)
Medullary thyroid cancer: options for systemic therapy of metastatic disease?
J. Clin. Oncol., Apr;24(11):1653-5 (2006)
Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Head Neck., Apr;28(4):305-12 (2006)
[11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
Ann. Surg. Oncol., Feb;13(2):187-97 (2006)
Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
J. Pharmacol. Exp. Ther., May;317(2):704-10 (2006)
The progress and promise of molecular imaging probes in oncologic drug development.
Clin. Cancer Res., Nov;11(22):7967-85 (2005)
True tracers: comparing FDG with glucose and FLT with thymidine.
Nucl. Med. Biol., Oct;32(7):663-71 (2005)
[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure.
Int. J. Radiat. Oncol. Biol. Phys., Mar;64(3):886-91 (2006)
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
Clin. Pharmacol. Ther., Jun;77(6):503-14 (2005)
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
Clin. Cancer Res., Apr;11(8):2785-808 (2005)
Evolving role of positron emission tomography in breast cancer imaging.
Semin Nucl Med., Apr;35(2):84-99 (2005)
Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
J. Nucl. Med., Feb;46(2):371-80 (2005)
Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
J. Nucl. Med., Feb;46(2):274-82 (2005)
PET imaging of cellular proliferation.
Radiol. Clin. North Am., Jan;43(1):153-67 (2005)
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
Cancer., Feb;103(4):680-8 (2005)
18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
J. Nucl. Med., Nov;45(11):1829-37 (2004)
Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
Acad Radiol., Oct;11(10):1115-24 (2004)
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
J. Nucl. Med., Oct;45(10):1653-9 (2004)
Comparison of different quantitative approaches to 18F-fluoride PET scans.
J. Nucl. Med., Sep;45(9):1493-500 (2004)
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).
Am. J. Clin. Oncol., Aug;27(4):407-10 (2004)
Current and future uses of positron emission tomography in breast cancer imaging.
Semin Nucl Med., Jul;34(3):224-40 (2004)
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
Clin. Cancer Res., Apr;10(7):2245-52 (2004)
Positron emission tomography imaging of brain tumors.
Neuroimaging Clin. N. Am., Nov;13(4):717-39 (2003)
Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?
Mol Imaging Biol., 5(5):281-5 (2003 Sep-Oct)
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
J. Nucl. Med., Nov;44(11):1806-14 (2003)